Tasly Transgene Biopharmaceuticals Co. Ltd. announced that it expects to receive funding from Tasly Pharmaceutical Group Co., Ltd. and another investor
Tasly Transgene Biopharmaceuticals (Tianjin) Co. Ltd. announced that it will receive an equity round of funding on December 2, 2016. The transaction will include participation from a returning investor, Tasly Pharmaceutical Group Co., Ltd. (SHSE:600535) and a French party. The transaction was approved in the 12th session of the 6th directorate meeting of Tasly Pharmaceutical Group Co., Ltd.